Talisman
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
More Information
- Trial Status
- Not currently accepting
- Trial Phase
- Phase 2
- Enrollment
- 130 patients (estimated)
- Sponsors
- Janssen Research & Development LLC
- Tags
- Bispecific Antibody, CD3, GPRC5D, Randomization
- Trial Type
- Treatment
- Last Update
- 3 days ago
- SparkCures ID
- 1950
- NCT Identifier
- NCT06500884
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.